American Journal of Cancer

, Volume 2, Issue 2, pp 87–94 | Cite as

Metastatic Prostate Cancer

Optimal Management Strategies
  • Brian M. Levin
  • David J. Vaughn
  • Bruce S. Malkowicz
Therapy in Practice


The treatment of metastatic prostate cancer is based upon the principle that prostate cancer growth is stimulated by androgens. Androgen ablation therapy is an effective treatment for metastatic prostate cancer. The timing of initiation of androgen ablation and the role of combined androgen blockade have been investigated. The utilization of intermittent androgen suppression offers the potential for improved quality of life. Intermittent therapy for metastatic disease is being compared with continuous therapy in an ongoing cooperative group trial. Recent studies have defined the evolving role of cytotoxic chemotherapy in hormone-refractory disease.


Androgen Androgen Receptor Finasteride Flutamide Metastatic Prostate Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Dr Vaughn receives research funding from Bristol-Myers Squibb Oncology and is on the speakers bureau of the Bristol-Myers Oncology and Eli Lilly and Company.

Dr Malkowicz is a consultant to AstraZeneca, Novartis, and Merck.


  1. 1.
    Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15–36PubMedCrossRefGoogle Scholar
  2. 2.
    Eder IE, Culig Z, Putz T, et al. Molecular biology of the androgen receptor: from molecular understanding to the clinic. Eur Utol 2001; 40(3): 241–51CrossRefGoogle Scholar
  3. 3.
    Bruchovsky N, Wilson JD. The conversion of testosterone to 5′-androstan-17′ol-3-one by rat prostate in vivo and in vitro. J Bioi Chem 1968; 243: 2012–7Google Scholar
  4. 4.
    Schroder F. Endocrine treatment of prostate cancer. In: Walsh PC, Vaughn ED, Retik A, et al., editors. Campbell’s urology. 7th ed. Philadelphia, (PA): W. B. Saunders, 1998; 3: 2627–44Google Scholar
  5. 5.
    Kyprianou N. Apoptosis: therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer. World J Urol 1994; 12(6): 299–303PubMedCrossRefGoogle Scholar
  6. 6.
    Sadar M, Hussain M, Bruchovsky N. Prostate cancer: molecular biology of early progression to androgen independence. Endocr Rel Cancer 1999; 6(4): 487–502CrossRefGoogle Scholar
  7. 7.
    Cassileth BR, Soloway MS, Vogelzang NJ, et al. Patients’ choice of treatment in stage D prostate cancer. Urology 1989; 33Suppl. 5: 57–62PubMedCrossRefGoogle Scholar
  8. 8.
    Robinson M, Smith P, Richards B, et al. The final analysis of the EORTC genitourinary tract cancer co-operative group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilbestrol in the management of metastatic carcinoma of the prostate. Eur Urol 1995; 28: 273–83PubMedGoogle Scholar
  9. 9.
    Bishop MC. Experience with low-dose estrogen in the treatment of advanced prostate cancer: a personal view. Br J Urol 1996; 78: 921–8PubMedCrossRefGoogle Scholar
  10. 10.
    Klotz L, McNeill I, Fleshner N, et al. A phase 1–2 trial of diethylstilibestrol plus low dose warfarin in advanced prostate carcinoma. J Urol 1999; 161: 169–72PubMedCrossRefGoogle Scholar
  11. 11.
    Miller JI, Ahmann FR, Drach GW, et al. The clinical usefulness of serum prostate-specific antigen after hormonal therapy of ruetastatic prostate cancer. J Urol 1992; 147: 956–61PubMedGoogle Scholar
  12. 12.
    Seidenfeld J, Samson D, Hasselblad V, et al. S ingle-therapy androgen suppression in men with advanced prostate cancer: a systematic review and roeta-analysis. Ann Intern Med 2000; 132(7): 566–77PubMedGoogle Scholar
  13. 13.
    Byar DP. Proceedings: The Veterans Administration Cooperative Urological Research Group’s studies of cancer of the prostate. Cancer 1973; 32(5): 1126–30PubMedCrossRefGoogle Scholar
  14. 14.
    Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engi J Med 1997; 337(5): 295–300CrossRefGoogle Scholar
  15. 15.
    Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectoray and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781–8PubMedCrossRefGoogle Scholar
  16. 16.
    The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997; 79(2): 235–46CrossRefGoogle Scholar
  17. 17.
    Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled triai of leuprolide with and without flutarnide in prostatic carcinoma. N Engi J Med 1989; 321(7): 419–24CrossRefGoogle Scholar
  18. 18.
    Eisenberger M, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without fiutamide for raetastatic prostate cancer. N Engl J Med 1998; 339(15): 1036–42PubMedCrossRefGoogle Scholar
  19. 19.
    Moinpour CM, Savage MJ, Troxel A, et al. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst 1998; 90(20): 1537–44PubMedCrossRefGoogle Scholar
  20. 20.
    Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized triais. Lancet 2000; 355: 1474–5CrossRefGoogle Scholar
  21. 21.
    Vale W, Grant G, Rivier J, et al. Synthetic polypeptide antagonist of the hypothalamic leutinizing hormone elated factor. Science 1972; 176: 933–4PubMedCrossRefGoogle Scholar
  22. 22.
    McLeod D, Zinner N, Gleason D, et al. Abarelix-depot versus leuprolide acetate for prostate cancer: results of a multi-institutional, randomized phase III study in 271 patients [abstract 1306]. Proc Am Soc Clin Oncol 2000; 19: 332AGoogle Scholar
  23. 23.
    Trachtenberg J, Gittelman M, Steidie C, et al. Ab arelix-depot versus leuprolide acetate plus bicalutamide for prostate cancer: results of a multi-institutional, randomized phase III study in 255 patients [abstract 1307]. Proc Am Soc Clin Oncol 2000; 19: 332AGoogle Scholar
  24. 24.
    Strieker HJ. Luteinizing hormone-releasing hormone antagonists in prostate cancer. Urology 2001; 58Suppl 2A: 24–7CrossRefGoogle Scholar
  25. 25.
    Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1642–5CrossRefGoogle Scholar
  26. 26.
    Daniell H. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology 2001; 58(2A): 101–7PubMedCrossRefGoogle Scholar
  27. 27.
    Bruchovsky N, Goldenberg SL, Gleave ME, et al. Intermitent therapy for prostate cancer. Endocr Rel Cancer 1957; 4: 1–25Google Scholar
  28. 28.
    Scher HE, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone refractory prostate cancer. J Clin Oncol 1993; 11(8): 1566–72PubMedGoogle Scholar
  29. 29.
    Taplin ME, Bubley GJ, Ko YJ, et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999; 59(11): 2511–5PubMedGoogle Scholar
  30. 30.
    Schroder FH, Collette L, de Reyke TM, et al. Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for the Research and Treatment of Cancer. Br J Cancer 2000; 82: 283–90PubMedCrossRefGoogle Scholar
  31. 31.
    Boccardo R, Rubagotti A, Barichello M, et al. Bicalutamide monotherapy versus flutarnide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 1999; 17: 2027–38PubMedGoogle Scholar
  32. 32.
    Brufsky A, Fontaine-Rothe P, Berlane K, et al. Finasteride and flutamide as potency-sparing androgen-albative therapy for advanced adenocarcinoma of the prostate. Urology 1995; 45: 491–7CrossRefGoogle Scholar
  33. 33.
    Fleshlier NE, Trachtenberg J. Combination finasteride and flutarnide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J Urology 1995; 154: 1642–6CrossRefGoogle Scholar
  34. 34.
    Lisle T, Mackenzie S, Ziada A, et al. Androgen deprivation therapy using finasteride and low dose flutarnide to treat PSA failure following therapy for clinically localized adenocarconoma of the prostate [abstract]. J Urology 1999; 161: 299CrossRefGoogle Scholar
  35. 35.
    Ornstein DK, Rao GS, Johnson B, et al. Combined finasteride and flutarnide therapy in men with advanced prostate cancer. Urology 1996; 48: 901–5PubMedCrossRefGoogle Scholar
  36. 36.
    Tannock IF, Osoba D, Stacker MR, et al. Chemotherapy with rnitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756–64PubMedGoogle Scholar
  37. 37.
    Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: results of the Cancer and Leukemia Group B. J Clin Oncol 1999; 17: 2506–13PubMedGoogle Scholar
  38. 38.
    Hudes G, Einhorn L, Ross E, et al. Vinblastine versus vinbiastine plus oral estrarnustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 1999; 17(10): 3160–6PubMedGoogle Scholar
  39. 39.
    Hudes GR, Nathan FE, Khater C, et al. Phase II Trial of 96 hour paclitaxel plus estramustine in metastatic hormone-refractory metastatic prostate cancer. J Clin Oncol 1997; 15: 3156–63PubMedGoogle Scholar
  40. 40.
    Hudes GR, Manola J, Conroy J, et al. Phase II study of weekly paclitaxel (P) by 1-hour infusion plus reduced dose oral estrarnsutine (EMP) in metastatic hormone-refractory prostate carcinoma: a trial of the Eastern Cooperative Oncology Group. Proc Am Soc Clin Oncol 2001; 20: 697aGoogle Scholar
  41. 41.
    Petryiak DP, Macarthur RB, O’Connor J, et al. Phase I trial of docetaxel with estrarnustine in androgen-independent prostate cancer. J Clin Oncol 1999; 17(3): 958–67Google Scholar
  42. 42.
    Hussain M, Petryiak D, Fisher E, et al. Docetaxel and estrarnustine versus rnitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. Sernin Oncol 1999; 26(5 Suppl. 17): 55–60Google Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • Brian M. Levin
    • 1
  • David J. Vaughn
    • 2
    • 3
  • Bruce S. Malkowicz
    • 1
  1. 1.Division of Urology, Department of SurgeryUniversity of Pennsylvania School of MedicinePhiladelphiaUSA
  2. 2.Division of Hematology/Oncology, Department of Medicine and the Abramsom Cancer CenterUniversity of Pennsylvania School of MedicinePhiladelphiaUSA
  3. 3.Abramson Cancer Center of the University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations